🧬 ABVX: That $3.16M "Call Buy" Was Only Half the Trade — a Ratio Spread That Wants $200, Not Beyond

📅 2026-08-11 | 🤝 Block Cross | Net Debit ≈$2.16M

🔄 Updated 2026-08-12 pre-market — the next-day OPRA open interest confirmed both legs, essentially to the contract. The December $140 calls opened 200 → 2,210 (+2,010 against a 2,000-lot buy); the December $200 calls opened 236 → 4,247 (+4,011 against a 4,000-lot sale). Both landed within ≈11 contracts of the published predictions of ≈2,200 and ≈4,236. The 1x2 ratio spread is a fully confirmed, fully new position at full size. See the ✅ RESOLVED box.

---

🎯 The Quick Take

The flow screen flagged a $3.16M purchase of 2,000 December $140 calls on ABVX and left it there — a clean, bullish-looking call buy. Scanning the full ABVX chain found what the screen missed: 4,000 December $200 calls sold at the exact same millisecond, printed at the bid for ≈$1.00M. The real position is a 1×2 call ratio spread — long one $140 call against two short $200 calls — for a net debit of ≈$2.16M, not a directional long-call bet. This trade makes its full money if ABVX is sitting at $200 on December 18. It does not want ABVX to keep climbing past that — beyond ≈$249.20 the desk is effectively net short a call, and the loss is open-ended.

---

🏢 Company Overview

ABVX is the Nasdaq-listed American Depositary Share of ABIVAX Société Anonyme, a French clinical-stage biotech (ordinary shares also trade on Euronext Paris). Its lead asset is obefazimod (ABX464), an oral, once-daily miR-124 enhancer in Phase 3 (ABTECT) for moderately-to-severely active ulcerative colitis, with a Phase 2b Crohn's program (ENHANCE-CD) behind it. Market cap is ≈$11.0B, sector Healthcare / Biotechnology, on ≈79.3M shares outstanding. The company just closed a $920M public offering (net ≈$874.1M, priced at $125.00/ADS) that it says extends its cash runway into Q4 2029, and it is hiring a U.S. commercial team to launch obefazimod without a Big Pharma partner. Because it is dual-listed, French-time press releases and occasional Euronext trading halts can move the ADS while Paris is closed — a structural source of overnight gap risk that matters for a December-expiry option.

---

💰 What Actually Printed — The Missing Leg

The flow screen surfaced one line. The tape shows two, executed together as a negotiated 🤝 block cross (a broker matched both sides off the open book — there is a known counterparty, this is not aggressive sweeping):

Net premium: ≈$2.16M debit ($3.16M paid − $1.00M collected). Gross dollars crossing the tape were $4.16M, but that double-counts the spread — the $2.16M debit is the actual capital at risk. Both legs were 🤝 block-crossed, negotiated off the lit book with a known counterparty on the other side — no urgency, no aggressive sweeping, just a worked package.

✅ RESOLVED — Both Legs Opened, Within ≈11 Contracts of the Published Prediction

Updated 2026-08-12 pre-market. Resolving OPRA snapshot timestamped August 12 (reflects the August 11 close, after this print); baseline is the August 11 snapshot (reflects the August 10 close, before this print).

Both strikes gained slightly more open interest than the blocks themselves, meaning essentially none of this size was existing holders trading against each other — it is close to 100% net-new contracts, plus a little extra flow that followed the block in. The ratio-spread read below stands at full size: 2,000 long $140 calls against 4,000 short $200 calls, a genuine new 1x2 structure rather than a repackaging of something that already existed.

Nothing in the analysis below needs revision.

---

🤓 What This Actually Means — Plain English

A 1×2 call ratio spread means: buy one call at a lower strike, sell two calls at a higher strike, same expiration. Here that's long the $140 call, short two $200 calls, financed by the $1.00M credit from the short calls against the $3.16M spent on the long call. Per 1×2 unit (one long, two short), the math is:

• Pay $15.80, collect $5.00 (2 × $2.50) → net debit $10.80/share (≈$1,080 per contract).
• Lower breakeven ≈$150.80. That's where the long $140 call's intrinsic value ($10.80) exactly covers the net debit. Because the short calls kicked in a credit, this breakeven sits ≈$5 cheaper than a plain long $140 call bought outright (which would break even at ≈$155.80) — the trade-off for that discount is the cap that follows.
• Maximum profit sits exactly at $200 at expiration: ≈$49.20/share (≈$4,920 per unit, ≈$9.84M across the full 2,000-unit package) — the long call is worth $60 and both short calls just expire worthless.
• Above $200, every extra dollar the stock gains costs the position, not helps it. With two short calls against one long call, the package becomes net short one call past the $200 strike. Profit erodes dollar-for-dollar with the stock above $200, crosses back to zero at ≈$249.20, and every dollar past that is an open-ended loss — there is no short-side hedge left to cap it.

The plain-English bottom line: this position wants ABVX to rise to $200 by December 18 and stop there. It is a bet on a specific price target, not on unlimited upside — which is unusual framing for a $126 stock with an active takeover speculation history and a binary regulatory filing on the calendar. Anyone reading the $3.16M headline alone would have missed that the same desk simultaneously capped its own gains and took on uncapped risk above $249.20.

---

📈 Technical Setup

ABVX's year has been a round trip, not a breakout: the stock cratered −44% on June 2 on a malignancy safety signal in Phase 3 data, then recovered almost the entire drawdown on June 29–30 when follow-up safety data eased the cancer concern. At ≈$126.19, the stock sits ≈1% above the $125.00 price of its own July secondary offering and roughly midway between its 52-week low ($67.15) and high ($148.83).

Gamma-based support & resistance

Per gex.json, dealer positioning is thin and concentrated close to spot. The only level flagged with real strength is $130 (moderate resistance, ≈2.9% above spot, net GEX ≈2.10) — call gamma there (2.79) heavily outweighs put gamma (0.69), consistent with dealers needing to sell into a rally toward $130. Further out, the $140 strike (the long leg of today's spread) shows a secondary net-gamma bump (total GEX ≈1.31, net ≈0.95, ≈10.8% above spot) — some of that is likely today's own new open interest. The $200 strike (the short leg) barely registers (total GEX ≈0.36, ≈58% above spot) — dealer hedging flows there are negligible, which is exactly what you'd expect from a strike this far out of the money and this early before expiration.

Implied move

implied_move.json prices the December 18 expiration itself as a Triple Witch OPEX date, with an implied range of $86.21 – $166.59 — a ≈32% move in either direction from spot. That is the important context for this spread: the $140 long strike (≈11% OTM) sits comfortably inside the market's own implied range, but the $200 short strike sits above the entire implied move ($166.59 upper bound), which is why the desk could sell it for only $2.50 — the market is pricing $200 as a genuinely low-probability outcome. Nearer-term, the market prices a ±11.97% move into the August 21 monthly OPEX ($111.27–$141.53) and a ±23.23% move into the September 18 Triple Witch ($97.04–$155.76).

---

🎪 Catalysts — Separating What's Confirmed From What's Estimated

The single most important fact for this trade: there is no confirmed clinical data readout or regulatory decision inside the December 18 window. What can fall inside it is a company-guided filing, not a coin-flip data event.

Already occurred (context, not upcoming)

• 2026-06-02: stock −44.10% on a malignancy safety signal in Phase 3 maintenance data.
• 2026-06-29: ABTECT Maintenance Part 2 results — malignancy rates framed as within published UC background ranges, which reversed most of the June 2 crash (Abivax).
• 2026-07-06: $920M ADS offering closed, net ≈$874.1M, priced at $125.00 (Abivax).
• 2026-07-30: positive pre-NDA interaction with the FDA; company reaffirmed submission "by end of 2026" (Abivax).

Inside the December 18 option window

Outside the window — the real binary events sit past expiry

Eleven analysts average a $165.91 price target (range $142–$187) (stockanalysis.com/forecast) — notably, Wedbush's Hold-rated target sits at exactly $140, the long strike of this spread, while the average target sits well short of the $200 short strike. This is a filing-confirmation and multiple-drift setup, not a scheduled data catalyst.

---

👥 Four Ways to Read This

🎰 YOLO Trader

Do not copy this as a simple bullish call buy — that is precisely the mistake the flow screen invites. If you want raw upside exposure into the NDA-filing window, buying the $140 call outright (without the short calls) costs more ($15.80 vs $10.80 net) but keeps unlimited upside. Replicating the actual package caps your gain at $200 and adds an open-ended loss above ≈$249.20 — a real risk in a name with live takeover speculation, where a surprise bid could gap the stock straight through your short strikes with no time to adjust.

📈 Swing Trader

The structure argues for watching the $130 gamma-resistance level first (per the gamma chart) and the $140 strike as the trade's own breakeven zone (≈$150.80 for the package to show a profit). If ABVX grinds toward $140–$160 into the September 21 earnings date and the Q4 filing news, the long leg gains steadily; the short calls stay a background drag only once price nears $200. This is a name to size cautiously — it already made a −44% one-day move once in 2026.

💰 Premium Collector

You didn't sell this — someone else did, collecting $2.50 per contract (≈$1.00M) on 4,000 December $200 calls that sit above the market's own ±32% implied move for that expiration. That is a defined, modest credit for taking on real tail risk if ABVX re-rates sharply (M&A, an accelerated filing, or a positive surprise). If you're inclined to sell premium on ABVX yourself, note the short strike here is already priced at the edge of "low probability" — selling closer to spot would need to weigh the binary-event risk this stock has already demonstrated it can deliver.

🔰 Beginner

This is a case study in why the headline number can mislead. "$3.16M call purchase" sounds like someone is betting ABVX goes up a lot. The full picture — a ratio spread — is a bet that ABVX goes up to a specific level and stays roughly there, with real financial risk if the stock keeps climbing past $249.20. Ratio spreads are a defined-risk-on-one-side, undefined-risk-on-the-other structure; they are not a beginner strategy, and this article is meant to help you read them correctly when you see them in flow, not to suggest replicating one.

---

⚠️ Honest Limits — What the Tape Cannot Prove

• The OPRA tape proves the two legs printed together as a cross and confirms price, size, and prior open interest. It cannot prove the trader's motive, whether this is a new position or an adjustment to an existing book, or whether the desk holds offsetting stock, other options, or a hedge elsewhere.
• Both legs look like proven opens on today's size-versus-OI margin, but a cross can still partially offset existing positions on either side — the next-session OI print is the only real confirmation, and this article will need revisiting if the actual OI move falls well short of the ≈2,200 / ≈4,236 projections above.
• Dealer gamma levels from gex.json are inferred from open interest and a sign convention, not observed market-maker positioning — treat $130 and $140 as probabilistic pressure zones, not hard walls.
• The NDA-submission timing is company-guided to a quarter, not a date; nothing here should be read as predicting an exact filing day.
• This is not a recommendation to open, close, or replicate this position. Options trading carries substantial risk of loss, ratio spreads carry open-ended risk on the short side, and clinical-stage biotech names can gap far beyond any strike on a single headline — size and risk-manage accordingly.

---

Last updated: 2026-08-12 (pre-market) — the next-day OPRA open-interest snapshot confirmed both legs. Dec-18 $140C 200 → 2,210 (+2,010 against a 2,000-lot buy): OPEN (BTO). Dec-18 $200C 236 → 4,247 (+4,011 against a 4,000-lot sale): OPEN (STO). Both inside the published prediction, so no thesis, title or tone changes were required; the ⏳ callout was replaced with the ✅ RESOLVED box.